Table 1.

Studies on COVID-19-patients with intensive care unit acquired myopathy.

	N of patients	Age mean (range) [years]	Sex	ICU stay mean (range) [days]	Medication	Clinical feature	NCS/EMG	Muscle biopsy	CK peak-level	IL-6 peak-level
(9)	7	NA	NA	NA	Antiretrovirals, neuromuscular blockers, corticosteroids, antibiotics	Generalized muscular weakness	Myopathy	Three patients (scattered necrotic and regenerative fibers, no inflammatory infiltrates)	181–3,228 μmol/l	N/A
(10)	5	N/A	N/A	N/A	Antirheumatics, antiretrovirals, corticosteroids, antibiotics	Generalized muscular weakness	Myopathy	ND	61–1,206 μg/l	NA
(8)	6	61 (51-72)	1 F	6-14 until NCS/EMG	Antirheumatics, antiretrovirals, corticosteroids, antibiotics, anticoagulants	Acute flaccid quadriplegia	Myopathy; reduced CMAP amplitude with markedly prolonged duration	ND	55–1,274 UI/L	18.4–5,402.2 ng/ml
(6)	1	68	M	65	Antibiotics	Severe symmetrical proximal and distal weakness and diffuse muscle wasting	Myopathy and bilateral peroneal compression neuropathy.	ND	NA	NA
(7)	1	62	F	30	Antirheumatics, antiretrovirals, antibiotics, neuromuscular blockers, antifungal drugs, corticosteroids.	Symmetrical muscle weakness predominant in lower limbs and proximal muscles.	Myopathy	ND	Normal	NA

ICU, intensive care unit; NCS/EMG, nerve conduction studies/electromyography; CK, creatine kinase; IL-6, interleukine 6; F, female; M, male; CMAP, compound muscle action potential; ND not done; NA not available.